Literature DB >> 21671987

Adult age and ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects.

Paul K L Chin1, Berit P Jensen, Helle S Larsen, Evan J Begg.   

Abstract

AIM: To see if adult age correlates with ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects.
METHODS: Sixty healthy drug free subjects were recruited in the age groups 18-39, 40-64 and ≥65 years. Plasma albumin concentrations were determined. Ex vivo unbound fractions (f(u)) were assessed by spiking samples and measuring the free and total concentrations.
RESULTS: No correlation of age with f(u) was seen. The study was powered to demonstrate a change in f(u) of ≥7-10%. A decline in plasma albumin concentration of ~0.03 g l(-1) year(-1) was seen with increasing age (P= 0.032) and was associated with increased f(u) of lorazepam (P= 0.009) and oxazepam (P= 0.014).
CONCLUSIONS: There was no association of adult age with ex vivo f(u) of lorazepam, oxazepam or temazepam in healthy subjects.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671987      PMCID: PMC3244648          DOI: 10.1111/j.1365-2125.2011.04036.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Effects of aging and liver disease on disposition of lorazepam.

Authors:  J W Kraus; P V Desmond; J P Marshall; R F Johnson; S Schenker; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1978-10       Impact factor: 6.875

3.  Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam.

Authors:  R B Smith; M Divoll; W R Gillespie; D J Greenblatt
Journal:  J Clin Psychopharmacol       Date:  1983-06       Impact factor: 3.153

4.  Effect of age and sex on lorazepam protein binding.

Authors:  M Divoll; D J Greenblatt
Journal:  J Pharm Pharmacol       Date:  1982-02       Impact factor: 3.765

5.  Effect of age and cardiopulmonary bypass on the pharmacokinetics of lorazepam.

Authors:  L Aaltonen; J Kanto; M Arola; E Iisalo; A Pakkanen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-08

6.  Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid.

Authors:  J Barré; J M Chamouard; G Houin; J P Tillement
Journal:  Clin Chem       Date:  1985-01       Impact factor: 8.327

7.  Lorazepam kinetics in the elderly.

Authors:  D J Greenblatt; M D Allen; A Locniskar; J S Harmatz; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

8.  Effect of age and gender on disposition of temazepam.

Authors:  M Divoll; D J Greenblatt; J S Harmatz; R I Shader
Journal:  J Pharm Sci       Date:  1981-10       Impact factor: 3.534

9.  Oxazepam kinetics: effects of age and sex.

Authors:  D J Greenblatt; M Divoll; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1980-10       Impact factor: 4.030

10.  Renal disease, age, and oxazepam kinetics.

Authors:  T G Murray; S T Chiang; H H Koepke; B R Walker
Journal:  Clin Pharmacol Ther       Date:  1981-12       Impact factor: 6.875

View more
  4 in total

1.  Predicted metabolic drug clearance with increasing adult age.

Authors:  Thomas M Polasek; Farhaan Patel; Berit P Jensen; Michael J Sorich; Michael D Wiese; Matthew P Doogue
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

2.  Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin.

Authors:  Berit Packert Jensen; Paul Ken Leong Chin; Rebecca Lee Roberts; Evan James Begg
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

3.  A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.

Authors:  A R Maharaj; J S Barrett; A N Edginton
Journal:  AAPS J       Date:  2013-01-24       Impact factor: 4.009

Review 4.  Impact of Changes in Free Concentrations and Drug-Protein Binding on Drug Dosing Regimens in Special Populations and Disease States.

Authors:  Marie N Celestin; Florin M Musteata
Journal:  J Pharm Sci       Date:  2021-06-02       Impact factor: 3.784

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.